| Literature DB >> 31963207 |
Claudia Peters1, Agnessa Kozak1, Albert Nienhaus1,2, Anja Schablon1.
Abstract
Healthcare workers (HCWs) have increased risk for latent tuberculosis infection (LTBI) and tuberculosis (TB) disease due to their occupational exposure. For some years now, interferon-γ release assays (IGRAs) have replaced the tuberculin skin test for the diagnosis of LTBI in many countries. This review examined the occupational risk of LTBI in HCWs with IGRA testing in low incidence countries. A systematic review and meta-analysis of studies from 2005 onwards provide data regarding the prevalence of LTBI in HCWs. In addition, the pooled effect estimates were calculated for individual regions and occupational groups. 57 studies with 31,431 HCWs from four regions and a total of 25 countries were analysed. The prevalence of LTBI varied from 0.9 to 85.5%. The pooled estimation found the lowest prevalence of LTBI for North American and West Pacific countries (<5%), and the highest prevalence for Eastern Mediterranean countries (19.4%). An increased risk for LTBI was found only for administrative employees. Studies on the occupational risk of LTBI continue to show increased prevalence of HCWs, even in low-incidence countries. Good quality studies will continue to be needed to describe occupational exposure.Entities:
Keywords: health personnel; interferon-gamma release assays (IGRA); latent tuberculosis infection (LTBI); low incidence countries; occupational risk
Mesh:
Year: 2020 PMID: 31963207 PMCID: PMC7027002 DOI: 10.3390/ijerph17020581
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flowchart of study selection process.
Studies of occupational latent tuberculosis infection (LTBI) with interferon-γ release assays (IGRAs) by WHO regions
| 1st Author, yr | Country | Study Design | Study Period | Setting | IGRA Used | No. of HCWs | No. of LTBI | Prevalence | 95% CI | Quality |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Fox 2009 [ | Israel | cross-sectional | 2007 | outpatient TB center | QFT-GIT | 100 | 17 | 17.0 | 10.8–25.7 | ++ |
| Soborg 2007 [ | Denmark | cross-sectional | 2007 | infectious disease ward | QFT-GIT | 139 | 2 | 1.4 | 0.7–5.4 | +++ |
| Gran 2013 [ | Norway | cross-sectional | 2008–09 | hospital/TB ward | QFT-GIT | 387 | 18 | 4.7 | 2.9–7.3 | +++ |
| Ciaschetti 2007 [ | Italy | cross-sectional | 2006–07 | hospital | QFT-GIT | 590 | 63 | 10.7 | 8.4–13.4 | +++ |
| Girardi 2009 [ | Italy | cross-sectional | 2004–05 | hospital/TB ward | QFT-GIT | 115 | 29 | 25.2 | 18.1–33.9 | +++ |
| Larcher 2012 [ | Italy | cross-sectional | 2006–07 | hospital | QFT-GIT | 621 | 115 | 18.5 | 15.7–21.8 | +++ |
| Sauzullo 2014 [ | Italy | cross-sectional | n/a | hospital | QFT-GIT | 196 | 34 | 17.3 | 12.7–23.3 | ++ |
| Magrini 2016 [ | Italy | cross-sectional | 2007–13 | hospital | QFT-GIT | 939 | 46 | 4.9 | 3.7–6.5 | n.a. |
| Stebler 2008 [ | Switzerland | retrospective | 2005–06 | hospital | QFT-GIT | 777 | 59 | 7.6 | 5.9–9.7 | +++ |
| Tripodi 2009 [ | France | cross-sectional | 2006–07 | hospital | QFT-GIT | 148 | 28 | 18.9 | 13.4–26.0 | +++ |
| Faibis 2011 [ | France | cross-sectional | 2008 | hospital | QFT-GIT | 137 | 16 | 11.7 | 7.2–18.2 | + |
| Moucaut 2013 [ | France | cross-sectional | 2007–11 | hospital | QFT-GIT | 634 | 141 | 22.2 | 19.2–25.6 | +++ |
| Nienhaus 2014 [ | France | prospective | 2008–13 | hospital | QFT-GIT | 1192 | 265 | 22.2 | 20.0–24.7 | +++ |
| Lucet 2015 [ | France | prospective | 2009–10 | hospital | QFT-GIT | 807 | 113 | 14.0 | 11.8–16.6 | ++ |
| Barsegian 2008 [ | Germany | cross-sectional | 2006 | radiology department | T-SPOT.TB | 95 | 1 | 1.1 | <0.01–6.3 | + |
| Schablon 2009 [ | Germany | cross-sectional | 2005–08 | TB hospital | QFT-GIT | 265 | 19 | 7.2 | 4.6–11.0 | +++ |
| Schablon 2011 [ | Germany | prospective | 2008–11 | nursing school | QFT-GIT | 194 | 4 | 2.1 | 0.6–5.4 | ++ |
| Schablon 2014 [ | Germany | prospective | 2006–13 | hospital + | QFT-GIT | 3823 | 318 | 8.3 | 7.5–9.2 | +++ |
| Herzmann 2017 [ | Germany | prospective | 2008–14 | respiratory hospital | QFT-GIT/ | 280 | 109 | 38.9 | 33.4–44.8 | ++ |
| Khanna 2009 [ | United Kingdom | cross-sectional | n/a | hospital | QFT-GIT | 171 | 13 | 7.6 | 4.4–12.7 | ++ |
| Alvarez-Leon 2009 [ | Spain | cross-sectional | 2007 | hospital | QFT-GIT | 134 | 8 | 5.97 | 2.9–11.5 | +++ |
| Casas 2009 [ | Spain | cross-sectional | 2004–05 | hospital | QFT-GIT | 147 | 43 | 29.3 | 22.5–37.1 | +++ |
| Martinez-Lacasa 2015 [ | Spain | cross-sectional | 2010–11 | hospital | QFT-GIT | 226 | 17 | 7.5 | 4.7–11.8 | ++ |
| Topic 2009 [ | Croatia | cross-sectional | 2007 | hospital | QFT-GIT | 54 | 17 | 31.5 | 20.6–44.8 | + |
| Targowski 2014 [ | Poland | cross-sectional | n/a | hospital | QFT-GIT | 305 | 27 | 8.9 | 6.1–12.6 | +++ |
| Ozdemir 2007 [ | Turkey | cross-sectional | 2005 | hospital | QFT-GIT | 76 | 65 | 85.5 | 78.7–71.9 | ++ |
| Caglayan 2011 [ | Turkey | cross-sectional | 2005 | TB hospital | QFT-GIT | 78 | 34 | 43.6 | 33.1–54.6 | + |
| Babayigit 2014 [ | Turkey | cross-sectional | n/a | hospital | QFT-GIT | 96 | 19 | 19.8 | 13.0–28.9 | +++ |
| Bozkanat 2016 [ | Turkey | cross-sectional | 2008 | TB hospital | QFT-GIT | 34 | 7 | 20.6 | 10.1–37.1 | + |
| Kargi 2017 [ | Turkey | cross-sectional | n/a | hospital | QFT-GIT | 100 | 23 | 23.0 | 15.8–32.2 | +++ |
| Torres Costa 2011 [ | Portugal | prospective | 2007–10 | hospital | QFT-GIT | 2884 | 953 | 33.0 | 31.4–34.8 | +++ |
| Nikolova 2013 [ | Bulgaria | cross-sectional | 2009 | TB hospital | QFT-GIT | 21 | 10 | 47.6 | 28.3–72.7 | + |
|
| ||||||||||
| Joshi 2012 [ | USA | retrospective | 2008–09 | hospital | QFT-GIT | 3290 | 129 | 3.9 | 3.3–4.6 | + |
| Dorman 2014 [ | USA | cross-sectional | 2008–11 | hospital | QFT-GIT | 2418 | 118 | 4.9 | 4.1–5.8 | ++ |
| Zwerling 2012 [ | Canada | cross-sectional | 2007–11 | hospital | QFT-GIT | 388 | 24 | 6.2 | 4.2–9.1 | +++ |
| Hernandez 2014 [ | Chile | cross-sectional | 2010–11 | hospital | QFT-GIT | 76 | 20 | 26.3 | 17.7–37.2 | + |
| Ochoa 2017 [ | Colombia | cross-sectional | 2013–15 | hospital | QFT-GIT | 988 | 466 | 47.2 | 44.1–50.3 | ++ |
|
| ||||||||||
| Vinton 2009 [ | Australia | cross-sectional | n/a | hospital | QFT-GIT | 481 | 32 | 6.7 | 4.7–9.3 | +++ |
| Freeman 2012 [ | New Zealand | cross-sectional | 2007–08 | hospital | QFT-GIT | 325 | 28 | 8.6 | 6.0–12.2 | +++ |
| Harada 2006 [ | Japan | cross-sectional | 2003 | hospital | QFT-GIT | 332 | 33 | 9.9 | 7.7–13.7 | +++ |
| Hotta 2007 [ | Japan | cross-sectional | 2006 | hospital | QFT-2G | 207 | 3 | 1.4 | 0.3–4.4 | ++ |
| Adachi 2013 [ | Japan | cross-sectional | 2011–12 | hospital | QFT-GIT | 165 | 18 | 10.9 | 6.9–16.7 | +++ |
| Ogiwara 2013 [ | Japan | retrospective | 2010–11 | hospital | QFT-GIT | 585 | 5 | 0.9 | 0.3–2.1 | ++ |
| Uto 2014 [ | Japan | prospective | 2007–10 | hospital | QFT-2G | 951 | 28 | 2.9 | 2.0–4.2 | +++ |
| Mukai 2017 [ | Japan | cross-sectional | 2008–11 | hospital | QFT-GIT | 140 | 6 | 4.3 | 1.8–9.2 | +++ |
| Tanabe 2017 [ | Japan | cross-sectional | 2015 | hospital | QFT-GIT | 654 | 19 | 2.9 | 1.8–4.5 | +++ |
|
| ||||||||||
| El-Helaly 2014 [ | Saudi Arabia | cross-sectional | 2009–11 | hospital | QFT-GIT | 1412 | 333 | 23.6 | 21.4–25.9 | +++ |
| Hassan 2014 [ | Saudi Arabia | cross-sectional | 2012 | laboratory | QFT-GIT | 134 | 26 | 19.4 | 13.6–27,0 | +++ |
| Al Hajoj 2016 [ | Saudi Arabia | cross-sectional | 2012–15 | hospital | QFT-GIT | 1595 | 399 | 25.0 | 23.0–27.2 | +++ |
| Bukhary 2018 [ | Saudi Arabia | cross-sectional | 2015 | hospital | QFT-GIT | 520 | 56 | 10.8 | 8.4–13.7 | ++ |
| El-Sokkary 2015 [ | Egypt | cross-sectional | 2012–13 | chest hospital/nephrology ward | QFT-GIT | 132 | 38 | 28.8 | 21.7–37.1 | +++ |
| Hefzy 2016 [ | Egypt | cross-sectional | 2015–16 | hospital | QFT-GIT | 39 | 4 | 10.3 | 3.5–24.2 | ++ |
| Talebi-Taher 2011 [ | Iran | cross-sectional | 2009–10 | hospital | QFT-GIT | 200 | 17 | 8.5 | 5.3–13.3 | +++ |
| Salmanzadeh 2016 [ | Iran | cross-sectional | n/a | hospital | QFT-GIT | 87 | 27 | 31.0 | 22.3–41.4 | + |
| Mostafavi 2016 [ | Iran | cross-sectional | 2013–14 | laboratory | QFT-GIT | 244 | 42 | 17.2 | 13.0–22.5 | +++ |
| Keshavarz Valian 2019 [ | Iran | cross-sectional | 2016 | hospital | QFT-GIT | 101 | 47 | 46,5 | 37.1-56.2 | + |
| Guanche Garcell 2014 [ | Qatar | cross-sectional | 2012–13 | hospital | QFT-GIT | 202 | 6 | 3.0 | 1.2–6.5 | ++ |
n/a—not available; Study quality: +++ high, ++ moderate, and + low quality.
Pooled prevalence estimations for LTBI by WHO regions.
| Studies (n) | Prevalence (%) | 95% CI | |
|---|---|---|---|
|
| |||
| All studies | 32 | 16.4 | 13.1–19.6 |
| Study quality (+++/++) | 25 | 16.3 | 12.6–20.1 |
| ≥139 participants | 20 | 13.9 | 10.1–17.7 |
|
| |||
| All studies | 5 | 16.5 | 9.8–23.2 |
| Study quality (+++/++) | 3 | 19.3 | 1.6–36.9 |
| ≥139 participants | 4 | 14.9 | 7.8–22.0 |
| North America | 3 | 4.5 | 3.8–5.2 |
|
| |||
| All studies | 9 | 4.8 | 3.0–6.6 |
| Study quality (+++/++) | 9 | 4.8 | 3.0–6.6 |
| ≥139 participants | 9 | 4.8 | 3.0–6.6 |
|
| |||
| All studies | 11 | 19.4 | 13.0–25.7 |
| Study quality (+++/++) | 9 | 16.1 | 9.5–22.7 |
| ≥139 participants | 7 | 15.2 | 7.9–22.6 |
Study quality: +++ high, ++ moderate.
Meta-analysis for job categories by WHO regions.
| WHO Region | Studies (n) | Job Category | Total HCWs | OR | 95% CI | I² |
|---|---|---|---|---|---|---|
|
| ||||||
|
| 20 | 1072/7077 | 15,262 | 0.87 | 0.72–1.05 | 59 |
|
| 10 | 608/4106 | 9099 | 0.80 | 0.63–1.02 | 56 |
|
| 4 | 52/1066 | 2102 | 0.85 | 0.58–1.26 | 0 |
|
| 6 | 412/1905 | 4061 | 1.01 | 0.74–1.38 | 53 |
|
| ||||||
|
| 19 | 442/2492 | 15,130 | 1.01 | 0.76–1.36 | 67 |
|
| 10 | 354/1616 | 9099 | 1.06 | 0.77–1.45 | 56 |
|
| 4 | 27/439 | 2102 | 1.09 | 0.50–2.39 | 50 |
|
| 5 | 61/437 | 3929 | 0.92 | 0.39–2.18 | 83 |
|
| ||||||
|
| 7 | 24/235 | 1732 | 1.01 | 0.58–1.77 | 28 |
|
| 3 | 9/136 | 583 | 0.67 | 0.29–1.56 | 12 |
|
| 2 | 7/33 | 497 | 2.57 | 1.05–6.29 | 0 |
|
| 2 | 8/66 | 652 | 0.74 | 0.34–1.65 | 0 |
|
| ||||||
|
| 7 | 222/901 | 10,145 | 1.60 | 1.18–2.17 | 37 |
|
| 4 | 195/696 | 7369 | 1.69 | 1.06–2.67 | 58 |
|
| 1 | 6 /100 | 951 | 2.41 | 0.95–6.08 | na |
|
| 2 | 21 /75 | 1795 | 1.41 | 0.83–2.38 | 0 |
Figure 2Forest plot of the LTBI prevalence in administrative employees by IGRA in low incidence countries.